Ouro Fino Saúde Animal Participações S.A (OFSA3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ouro Fino Saúde Animal Participações S.A (OFSA3) has a cash flow conversion efficiency ratio of 0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$99.91 Million ≈ $19.60 Million USD) by net assets (R$796.86 Million ≈ $156.36 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ouro Fino Saúde Animal Participações S.A - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Ouro Fino Saúde Animal Participações S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Ouro Fino Saúde Animal Participações S.A total liabilities for a breakdown of total debt and financial obligations.
Ouro Fino Saúde Animal Participações S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ouro Fino Saúde Animal Participações S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fiera Capital Corporation
TO:FSZ
|
0.138x |
|
Jiangsu Holly Corp
SHG:600128
|
0.038x |
|
Test Rite International Co Ltd
TW:2908
|
0.132x |
|
Universal Vision Biotechnology Co Ltd
TWO:3218
|
0.125x |
|
Nordic Paper Holding AB
ST:NPAPER
|
0.115x |
|
Prudential plc
LSE:PRU
|
0.073x |
|
AzureWave Technologies Inc
TW:3694
|
0.076x |
|
Matrix Service Co
NASDAQ:MTRX
|
0.245x |
Annual Cash Flow Conversion Efficiency for Ouro Fino Saúde Animal Participações S.A (2011–2025)
The table below shows the annual cash flow conversion efficiency of Ouro Fino Saúde Animal Participações S.A from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see OFSA3 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$796.86 Million ≈ $156.36 Million |
R$99.91 Million ≈ $19.60 Million |
0.125x | +28.27% |
| 2024-12-31 | R$756.40 Million ≈ $148.42 Million |
R$73.94 Million ≈ $14.51 Million |
0.098x | -64.59% |
| 2023-12-31 | R$689.39 Million ≈ $135.27 Million |
R$190.30 Million ≈ $37.34 Million |
0.276x | +126.76% |
| 2022-12-31 | R$735.95 Million ≈ $144.41 Million |
R$89.59 Million ≈ $17.58 Million |
0.122x | +67.93% |
| 2021-12-31 | R$641.45 Million ≈ $125.86 Million |
R$46.50 Million ≈ $9.12 Million |
0.072x | -63.68% |
| 2020-12-31 | R$560.78 Million ≈ $110.03 Million |
R$111.94 Million ≈ $21.96 Million |
0.200x | +74.32% |
| 2019-12-31 | R$492.45 Million ≈ $96.63 Million |
R$56.39 Million ≈ $11.06 Million |
0.115x | +21.96% |
| 2018-12-31 | R$455.94 Million ≈ $89.46 Million |
R$42.81 Million ≈ $8.40 Million |
0.094x | -61.70% |
| 2017-12-31 | R$405.88 Million ≈ $79.64 Million |
R$99.50 Million ≈ $19.52 Million |
0.245x | +118.41% |
| 2016-12-31 | R$376.33 Million ≈ $73.84 Million |
R$42.24 Million ≈ $8.29 Million |
0.112x | +175.25% |
| 2015-12-31 | R$380.31 Million ≈ $74.62 Million |
R$15.51 Million ≈ $3.04 Million |
0.041x | +1478.41% |
| 2014-12-31 | R$330.16 Million ≈ $64.78 Million |
R$853.00K ≈ $167.37K |
0.003x | -98.38% |
| 2013-12-31 | R$209.42 Million ≈ $41.09 Million |
R$33.45 Million ≈ $6.56 Million |
0.160x | -6.07% |
| 2012-12-31 | R$194.84 Million ≈ $38.23 Million |
R$33.13 Million ≈ $6.50 Million |
0.170x | +114.04% |
| 2011-12-31 | R$177.44 Million ≈ $34.82 Million |
R$14.10 Million ≈ $2.77 Million |
0.079x | -- |
About Ouro Fino Saúde Animal Participações S.A
Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including an… Read more